July 24, 2014 / 11:51 AM / 3 years ago

Celgene profit rises 25 pct up on higher cancer drug sales

July 24 (Reuters) - Celgene Corp reported a 25 percent increase in quarterly profit, helped by robust sales of its flagship cancer drug, Revlimid.

The U.S. biotechnology company’s net profit rose to $597.8 million, or 72 cents per share, in the second quarter ended June 30, from $478.1 million, or 56 cents per share, a year earlier.

Excluding special items, it earned 90 cents per share.

Total revenue rose 17 percent to $1.87 billion.

Sales of multiple myeloma treatment Revlimid rose 15 percent to $1.21 billion. (Reporting by Anand Basu in Bangalore; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below